Flash Finance

SMS Pharmaceuticals LimitedSMSPHARMACorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹450.50
MCap ₹4,219 Cr · P/E 46.6
SMS Pharmaceuticals Limited — Stock analysis & AI research SMS Pharmaceuticals Limited — Multibagger AI analysis SMS Pharmaceuticals Limited — Seasonality — best & worst months SMS Pharmaceuticals Limited — Technical indicators & charts SMS Pharmaceuticals Limited — Technical setup — score, trend, support & resistance SMS Pharmaceuticals Limited — Live exchange announcements
📋 Promoters Increasing Stake📋 High Promoter Holding Stocks 📈 Strong Trend Stocks (ADX > 25)📈 Bullish EMA Alignment📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹207 Cr
Sales · Jun 2026
+5.6% YoY
₹42 Cr
Operating Profit · Jun 2026
+7.8% YoY
20.2%
OPM % · Jun 2026
+2.0% YoY
₹21 Cr
Net Profit · Jun 2026
+16.1% YoY
₹2.26
EPS · Jun 2026
+10.2% YoY

📝 SMS Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

SMS Pharmaceuticals Limited reported revenue of ₹207 crore for the quarter ended June 2026 (Q1 FY27), up 5.6% from ₹196 crore in the same quarter last year, and down 13.0% sequentially over the March 2026 quarter.

Net profit rose 16.1% year-on-year to ₹21 crore, from ₹18 crore. Earnings per share (EPS) came in at ₹2.26.

Operating profit stood at ₹42 crore — an operating margin (OPM) of 20.2%, compared with 19.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, SMS Pharmaceuticals Limited posted revenue of ₹887 crore, a growth of 13.3% over FY25, with a net profit of ₹88 crore (up 27.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹898 crore with a net profit of ₹91 crore.

Valuation snapshot

At the current price of ₹450.50, SMSPHARMA has a market capitalisation of ₹4,219 crore and a trailing P/E of about 46.6.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the largest of the 11 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 68.07%, foreign institutional investors (FIIs) 1.18%, domestic institutional investors (DIIs) 0.20%, public shareholders 30.56% of SMS Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,219 Cr
Current Price ?
₹450.5
P/E ?
46.56above ind
Industry P/E ?
32.10
P/B ?
5.25
P/S ?
4.70
P/FCF ?
-65.92
Enterprise Value ?
₹4,584 Cr
EV/EBITDA ?
26.34
PEG ?
0.26
Earnings Yield ?
2.9%
Dividend Yield ?
0.09%
Profitability & Returns
Sales (TTM) ?
₹898 Cr
OPM ?
19.4%
Profit after tax (TTM) ?
₹91 Cr
EPS (TTM) ?
₹9.68
ROCE ?
13.0%
ROE ?
11.3%
ROA ?
6.6%
Growth
Sales — latest qtr ?
₹207 Cr
PAT — latest qtr ?
₹21 Cr
YoY qtr sales growth ?
5.6%
YoY qtr profit growth ?
16.1%
Sales growth (3y) ?
19%
Sales growth (5y) ?
10%
Profit growth (3y) ?
177%
Profit growth (5y) ?
8%
Financial Health
Debt ?
₹365 Cr
Debt to Equity ?
0.45
Interest Coverage ?
5.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
68.07%
Change in promoter holding ?
1.80%
Pledged percentage ?
N/A
Market
Return 3 months ?
16.2%
Return 6 months ?
5.0%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 149149135167161246164197173248196242210238207 +5.6% -13.0%
Operating Profit 182327282933333233413948444042 +7.8% +4.7%
Other Income 211112112111432 +194.1% -41.9%
Interest 666666554566655 -5.8% +10.0%
Depreciation 88888889991010101010 +2.4% -0.1%
Profit Before Tax 61113151622222023292434312728 +17.9% +4.2%
Net Profit 589121216161417211825232121 +16.1% +0.6%
EPS 0.590.951.101.421.441.881.931.682.032.332.052.822.572.232.26 +10.2% +1.3%
OPM % 12.3% 15.6% 19.7% 16.7% 17.9% 13.6% 20.3% 16.2% 19.2% 16.5% 19.8% 20.0% 20.8% 16.8% 20.2% +2.0% +20.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹783 Cr ₹887 Cr ₹898 Cr +13.3%
Operating Profit ₹140 Cr ₹171 Cr ₹174 Cr +22.5%
OPM % 17.84% 19.28% 19.39% +8.1%
NPM % 8.79% 9.89% 10.09% +12.5%
Other Income ₹6 Cr ₹9 Cr ₹10 Cr +51.4%
Depreciation ₹35 Cr ₹40 Cr ₹40 Cr +14.7%
Interest ₹18 Cr ₹23 Cr ₹22 Cr +23.4%
EBIT ₹105 Cr ₹131 Cr ₹134 Cr +25.1%
PBT ₹93 Cr ₹116 Cr ₹121 Cr +24.6%
Tax ₹16 Cr ₹23 Cr ₹24 Cr +36.6%
Net Profit ₹69 Cr ₹88 Cr ₹91 Cr +27.5%
EPS ₹7.97 ₹9.67 ₹9.88 +21.3%
Material Cost ₹384 Cr ₹393 Cr ₹381 Cr +2.4%
Employee Cost ₹53 Cr ₹58 Cr ₹64 Cr +9.4%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 8899 +0.0%
Reserves 487562664795 +19.7%
Borrowings 254281311365 +17.4%
Other Liabilities 165217202211 +4.5%
Total Liabilities 9141,0681,1861,381 +16.4%
Fixed Assets 412437533534 +0.2%
CWIP 333035116 +231.4%
Investments 45454552 +15.6%
Other Assets 424556573679 +18.5%
Total Assets 9141,0681,1861,381 +16.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 22508261 -25.6%
Cash from Investing Activity -30-52-123-132 -7.3%
Cash from Financing Activity -32314776 +61.7%
Net Cash Flow -392954 -20.0%
Free Cash Flow -7-2-42-64 -52.4%
CFO/OP 49%56%73%50% -31.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1041229589 -6.3%
Inventory Days 243201238259 +8.8%
Days Payable 1171309589 -6.3%
Cash Conversion Cycle 230192238259 +8.8%
Working Capital Days 104858898 +11.4%
ROCE % 4%11%12%13% +8.3%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 66.27%68.07%68.07%68.07%68.07% +0.0%
FIIs 0.03%0.28%0.04%0.31%1.18% +280.6%
DIIs 3.03%2.88%3.21%3.02%0.20% -93.4%
Public 30.68%28.77%28.69%28.60%30.56% +6.9%
No. of Shareholders 33,65234,15734,37832,39734,904 +7.7%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SMSPHARMA SMS Pharmaceuticals ₹442.45 4,144 39.7 898 102 19.3% 11.4% 13.3% 48.6% 5.6% -1.4%
2 AARTIDRUGS Aarti Drugs ₹428.30 3,909 20.5 2,678 191 12.4% 7.1% 7.5% 16.3% 18.9% -7.2%
3 HIKAL Hikal ₹229.83 2,834 — 1,734 -34 13.4% -2.0% -8.0% -154.4% 6.0% 67.0%
4 BETA Beta Drugs ₹2,064.90 2,084 37.5 513 57 20.5% 11.2% — — 25.5% 31.7%
5 NGLFINE NGL Fine-Chem ₹2,786.60 1,722 30.1 536 57 15.6% 10.6% 36.0% 123.2% 33.6% 99.1%
6 ANUHPHR Anuh Pharma ₹92.99 932 21.1 779 44 8.6% 5.7% 16.5% -12.8% 4.2% 42.8%
7 INFINIUM Infinium Pharma ₹222.95 347 31.2 190 14 11.3% 7.2% — — 45.2% 166.7%
8 AAREYDRUGS Aarey Drugs ₹98.71 329 67.1 415 4 1.6% 1.0% -0.4% 12.3% -56.3% -25.3%
9 PAR Par Drugs ₹128.90 159 10.9 109 14 18.3% 13.3% 2.7% -1.9% 20.1% 41.6%
10 KREBSBIO Krebs Biochemicals ₹57.94 125 — 25 -14 -10.0% -55.9% -45.2% 37.1% 27.4% 53.3%
11 VILINBIO Vilin Bio ₹18.00 27 14.2 42 2 7.6% 4.6% — — 215.9% 1680.0%
❓ Frequently asked questions
What was SMS Pharmaceuticals Limited's revenue in Q1 FY27?
SMS Pharmaceuticals Limited reported revenue of ₹207 crore for the quarter ended June 2026 (Q1 FY27), up 5.6% from ₹196 crore in the same quarter last year, and down 13.0% sequentially over the March 2026 quarter.
What was SMS Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 16.1% year-on-year to ₹21 crore, from ₹18 crore. Earnings per share (EPS) came in at ₹2.26.
What is SMSPHARMA's market capitalisation and P/E ratio?
At the current price of ₹450.50, SMSPHARMA has a market capitalisation of ₹4,219 crore and a trailing P/E of about 46.6.
Who owns SMS Pharmaceuticals Limited? (shareholding pattern)
As of Sep 2026, promoters held 68.07%, foreign institutional investors (FIIs) 1.18%, domestic institutional investors (DIIs) 0.20%, public shareholders 30.56% of SMS Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI